Tags: Drug.
Entolimod (CBLB502) is being developed by Cleveland Biolabs Inc. for dual indications under the U.S. Food & Drug Administration’s (FDA) Animal Efficacy Rule as a pivotal-stage radiation countermeasure and under the FDA’s traditional drug approval pathway as a targeted cancer treatment.Entolimod is an engineered derivative of the Salmonella flagellin protein that induces a spectrum of protective effects upon direct interaction and signaling via toll-like receptor 5 (TLR5).